David A. Solomon

David A. Solomon

Auto-generated profile, based on publicly available information

David A. Solomon

University of California, San Francisco 8 Department of Pathology San Francisco, California

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2020 in Brain Pathology
Verified
Journal Article
Closed access
PDF file
DLDavid N. Louis
David N. Louis
PWPieter Wesseling
Pieter Wesseling
KAKenneth Aldape
Kenneth Aldape
DBDaniel J. Brat
Daniel J. Brat
DCDavid Capper
David Capper
DEDavid W. Ellison
David W. Ellison

20 December 2022 in Nature Cancer
Verified
Journal Article
Open access
PDF file
LWLin Wang
Lin Wang
JJJangham Jung
Jangham Jung
HBHusam Babikir
Husam Babikir
KSKarin Shamardani
Karin Shamardani
SJSaket Jain
Saket Jain
ADAaron A. Diaz
Aaron A. Diaz
Recent longitudinal studies of glioblastoma (GBM) have demonstrated a lack of apparent selection pressure for specific DNA mutations in recurrent disease. Single-cell lineage tracing has shown that GBM cells possess a high degree of plasticity. Together this suggests that phenotype switching, as opposed to genetic evolution, may be the escape mechanism that explains the failure of precision therapies to date. We profiled 86 primary-recurrent patient-matched paired GBM specimens with single-nucleus RNA, single-cell open-chromatin, DNA and spatial transcriptomic/proteomic assays. We found that recurrent GBMs are characterized by a shift to a mesenchymal phenotype. We show that the mesenchymal state is mediated by activator protein 1. Increased T-cell abundance at recurrence was prognostic and correlated with hypermutation status. We identified tumor-supportive networks of paracrine and autocrine signals between GBM cells, nonmalignant neuroglia and immune cells. We present cell-intrinsic and cell-extrinsic targets and a single-cell multiomics atlas of GBM under therapy.

9 May 2022 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
ACAbrar Choudhury
Abrar Choudhury
Stephen T. MagillStephen T. Magill
Stephen T. Magill
CECharlotte D. Eaton
Charlotte D. Eaton
BPBriana C. Prager
Briana C. Prager
WCWilliam C. Chen
William C. Chen
DRDavid R. Raleigh
David R. Raleigh

1 July 2020 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
MCMatthew Clarke
Matthew Clarke
AMAlan Mackay
Alan Mackay
BIBritta Ismer
Britta Ismer
JPJessica Pickles
Jessica Pickles
RTRuth G. Tatevossian
Ruth G. Tatevossian
CJChris Jones
Chris Jones
Infant high-grade gliomas appear clinically distinct from their counterparts in older children, indicating that histopathologic grading may not accurately reflect the biology of these tumors. We have collected 241 cases under 4 years of age, and carried out histologic review, methylation profiling, and custom panel, genome, or exome sequencing. After excluding tumors representing other established entities or subgroups, we identified 130 cases to be part of an “intrinsic” spectrum of disease specific to the infant population. These included those with targetable MAPK alterations, and a large proportion of remaining cases harboring gene fusions targeting ALK (n = 31), NTRK1/2/3 (n = 21), ROS1 (n = 9), and MET (n = 4) as their driving alterations, with evidence of efficacy of targeted agents in the clinic. These data strongly support the concept that infant gliomas require a change in diagnostic practice and management. Significance: Infant high-grade gliomas in the cerebral hemispheres comprise novel subgroups, with a prevalence of ALK, NTRK1/2/3, ROS1, or MET gene fusions. Kinase fusion–positive tumors have better outcome and respond to targeted therapy clinically. Other subgroups have poor outcome, with fusion-negative cases possibly representing an epigenetically driven pluripotent stem cell phenotype. See related video: https://vimeo.com/438254885 See related commentary by Szulzewsky and Cimino, p. 904. This article is highlighted in the In This Issue feature, p. 890

7 June 2018 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
MPMelike Pekmezci
Melike Pekmezci
JVJavier E. Villanueva-Meyer
Javier E. Villanueva-Meyer
BGBenjamin Goode
Benjamin Goode
JZJessica Van Ziffle
Jessica Van Ziffle
COCourtney Onodera
Courtney Onodera
DSDavid A. Solomon
David A. Solomon
Ganglioglioma is the most common epilepsy-associated neoplasm that accounts for approximately 2% of all primary brain tumors. While a subset of gangliogliomas are known to harbor the activating p.V600E mutation in the BRAF oncogene, the genetic alterations responsible for the remainder are largely unknown, as is the spectrum of any additional cooperating gene mutations or copy number alterations. We performed targeted next-generation sequencing that provides comprehensive assessment of mutations, gene fusions, and copy number alterations on a cohort of 40 gangliogliomas. Thirty-six harbored mutations predicted to activate the MAP kinase signaling pathway, including 18 with BRAF p.V600E mutation, 5 with variant BRAF mutation (including 4 cases with novel in-frame insertions at p.R506 in the β3-αC loop of the kinase domain), 4 with BRAF fusion, 2 with KRAS mutation, 1 with RAF1 fusion, 1 with biallelic NF1 mutation, and 5 with FGFR1/2 alterations. Three gangliogliomas with BRAF p.V600E mutation had concurrent CDKN2A homozygous deletion and one additionally harbored a subclonal mutation in PTEN. Otherwise, no additional pathogenic mutations, fusions, amplifications, or deletions were identified in any of the other tumors. Amongst the 4 gangliogliomas without canonical MAP kinase pathway alterations identified, one epilepsy-associated tumor in the temporal lobe of a young child was found to harbor a novel ABL2-GAB2 gene fusion. The underlying genetic alterations did not show significant association with patient age or disease progression/recurrence in this cohort. Together, this study highlights that ganglioglioma is characterized by genetic alterations that activate the MAP kinase pathway, with only a small subset of cases that harbor additional pathogenic alterations such as CDKN2A deletion.

14 November 2016 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
CKCassie N. Kline
Cassie N. Kline
NJNancy M. Joseph
Nancy M. Joseph
JGJames P. Grenert
James P. Grenert
JZJessica van Ziffle
Jessica van Ziffle
ETEric Talevich
Eric Talevich
DSDavid A. Solomon
David A. Solomon
Molecular profiling is revolutionizing cancer diagnostics and leading to personalized therapeutic approaches. Herein we describe our clinical experience performing targeted sequencing for 31 pediatric neuro-oncology patients. We sequenced 510 cancer-associated genes from tumor and peripheral blood to identify germline and somatic mutations, structural variants, and copy number changes. Genomic profiling was performed on 31 patients with tumors including 11 high-grade gliomas, 8 medulloblastomas, 6 low-grade gliomas, 1 embryonal tumor with multilayered rosettes, 1 pineoblastoma, 1 uveal ganglioneuroma, 1 choroid plexus carcinoma, 1 chordoma, and 1 high-grade neuroepithelial tumor. In 25 cases (81%), results impacted patient management by: (i) clarifying diagnosis, (ii) identifying pathogenic germline mutations, or (iii) detecting potentially targetable alterations. The pathologic diagnosis was amended after genomic profiling for 6 patients (19%), including a high-grade glioma to pilocytic astrocytoma, medulloblastoma to pineoblastoma, ependymoma to high-grade glioma, and medulloblastoma to CNS high-grade neuroepithelial tumor with BCOR alteration. Multiple patients had pathogenic germline mutations, many of which were previously unsuspected. Potentially targetable alterations were identified in 19 patients (61%). Additionally, novel likely pathogenic alterations were identified in 3 cases: an in-frame RAF1 fusion in a BRAF wild-type pleomorphic xanthoastrocytoma, an inactivating ASXL1 mutation in a histone H3 wild-type diffuse pontine glioma, and an in-frame deletion within exon 2 of MAP2K1 in a low-grade astrocytic neoplasm. Our experience demonstrates the significant impact of molecular profiling on diagnosis and treatment of pediatric brain tumors and confirms its feasibility for use at the time of diagnosis or recurrence.